×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
LLY – eli lilly and company (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
LLY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/24
07:01 pm
lly
Eli Lilly and Company (LLY) is now covered by Royal Bank Of Canada. They set an "outperform" rating on the stock.
Low
Report
Eli Lilly and Company (LLY) is now covered by Royal Bank Of Canada. They set an "outperform" rating on the stock.
2/24
12:53 pm
lly
Novo downgraded at J.P. Morgan as next-gen obesity drug trails Lilly's Zepbound [Seeking Alpha]
Low
Report
Novo downgraded at J.P. Morgan as next-gen obesity drug trails Lilly's Zepbound [Seeking Alpha]
2/24
12:16 am
lly
Analysis-Novo's stumbles burnish Lilly's widening lead in weight-loss drugs [Yahoo! Finance Canada]
Low
Report
Analysis-Novo's stumbles burnish Lilly's widening lead in weight-loss drugs [Yahoo! Finance Canada]
2/23
10:25 am
lly
Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen [MSNBC.com]
Low
Report
Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen [MSNBC.com]
2/23
09:02 am
lly
Eli Lilly launches new form of obesity drug Zepbound with a month's worth of doses in one pen [CNBC]
Low
Report
Eli Lilly launches new form of obesity drug Zepbound with a month's worth of doses in one pen [CNBC]
2/23
09:00 am
lly
Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen
Low
Report
Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen
2/23
06:13 am
lly
Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly's in trial [MSNBC.com]
Low
Report
Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly's in trial [MSNBC.com]
2/21
12:38 pm
lly
Eli Lilly's Landmark Trial Shows Major Psoriasis-Obesity Breakthrough With Taltz-Zepbound Combo [Yahoo! Finance]
Medium
Report
Eli Lilly's Landmark Trial Shows Major Psoriasis-Obesity Breakthrough With Taltz-Zepbound Combo [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/19
04:19 pm
lly
Form 4 ELI LILLY & Co For: Feb 19 Filed by: Dozier Eric
Low
Report
Form 4 ELI LILLY & Co For: Feb 19 Filed by: Dozier Eric
2/18
04:27 pm
lly
Form 4 ELI LILLY & Co For: Feb 17 Filed by: Sulzberger Gabrielle
Low
Report
Form 4 ELI LILLY & Co For: Feb 17 Filed by: Sulzberger Gabrielle
2/18
04:26 pm
lly
Form 4 ELI LILLY & Co For: Feb 17 Filed by: LUCIANO JUAN R
Low
Report
Form 4 ELI LILLY & Co For: Feb 17 Filed by: LUCIANO JUAN R
2/18
04:25 pm
lly
Form 4 ELI LILLY & Co For: Feb 17 Filed by: Fyrwald J Erik
Low
Report
Form 4 ELI LILLY & Co For: Feb 17 Filed by: Fyrwald J Erik
2/18
04:24 pm
lly
Form 4 ELI LILLY & Co For: Feb 17 Filed by: Alvarez Ralph
Low
Report
Form 4 ELI LILLY & Co For: Feb 17 Filed by: Alvarez Ralph
2/18
04:23 pm
lly
Form 4 ELI LILLY & Co For: Feb 16 Filed by: Zakrowski Donald A
Low
Report
Form 4 ELI LILLY & Co For: Feb 16 Filed by: Zakrowski Donald A
2/18
04:22 pm
lly
Form 4 ELI LILLY & Co For: Feb 16 Filed by: Montarce Lucas
Low
Report
Form 4 ELI LILLY & Co For: Feb 16 Filed by: Montarce Lucas
2/18
04:21 pm
lly
Form 4 ELI LILLY & Co For: Feb 16 Filed by: Custer Kenneth L.
Low
Report
Form 4 ELI LILLY & Co For: Feb 16 Filed by: Custer Kenneth L.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/12
Eli Lilly, AbCellera Biologics to co-develop coronavirus therapies [Reuters]
14.2%
3/2 U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis 5.8%
4/13 Despite Qualms, Arthritis Drug to Be Tested in Coronavirus Study [The New York Times] 4.6%
4/2 Eli Lilly And Co (NYSE: LLY) had its price target lowered by analysts at Morgan Stanley from $150.00 to $148.00. They now have an "overweight" rating on the stock. 4.2%
3/23 FDA enacts abbreviated approval pathway for insulin biosimilars [Seeking Alpha] 3.2%
4/16 Lower-priced versions of Humalog® Mix75/25™ KwikPen® and Humalog® Junior KwikPen® now available 3.2%
10/28 Insider Buying: The Eli Lilly and Company (NYSE:LLY) Chairman Just Bought US$500k Worth Of Shares [Yahoo! Finance News] 2.7%
2/4 Form 4 ELI LILLY & Co For: Feb 01 Filed by: Zulueta Alfonso G 2.7%
12/18 Lilly Announces the Launch of TRIUMPH, the First, Long-Term, Real-World Evidence Study of Emgality® (galcanezumab-gnlm) 2.7%
3/23 Lilly Provides Update on Clinical Trial Activities During COVID-19 Pandemic 2.6%
3/2 U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis 5.8%
4/13 Despite Qualms, Arthritis Drug to Be Tested in Coronavirus Study [The New York Times] 4.6%
4/2 Eli Lilly And Co (NYSE: LLY) had its price target lowered by analysts at Morgan Stanley from $150.00 to $148.00. They now have an "overweight" rating on the stock. 4.2%
3/23 FDA enacts abbreviated approval pathway for insulin biosimilars [Seeking Alpha] 3.2%
4/16 Lower-priced versions of Humalog® Mix75/25™ KwikPen® and Humalog® Junior KwikPen® now available 3.2%
10/28 Insider Buying: The Eli Lilly and Company (NYSE:LLY) Chairman Just Bought US$500k Worth Of Shares [Yahoo! Finance News] 2.7%
2/4 Form 4 ELI LILLY & Co For: Feb 01 Filed by: Zulueta Alfonso G 2.7%
12/18 Lilly Announces the Launch of TRIUMPH, the First, Long-Term, Real-World Evidence Study of Emgality® (galcanezumab-gnlm) 2.7%
3/23 Lilly Provides Update on Clinical Trial Activities During COVID-19 Pandemic 2.6%
TOP News Decliners
3/11
Eli Lilly to Participate in Program to Make Insulin Cheaper for Seniors [The Motley Fool]
-10.0%
3/18 Hap Sneddon's Top Picks: March 18, 2020 [Business News Network (BNN) Energy & Resources (Canada)] -7.6%
3/20 Form DEFA14A ELI LILLY & Co -5.8%
7/11 New England Journal of Medicine Publishes Positive Phase 3 Data for Emgality® (galcanezumab-gnlm) in Episodic Cluster Headache -5.3%
6/9 Lilly's ultra rapid lispro provided similar A1C reductions compared to Humalog® (insulin lispro), with superior post-meal blood glucose reductions -4.0%
8/14 Lilly Launches Open Innovation Challenge to Help Transform Inflammatory Bowel Disease (IBD) Care through Digital Health -4.0%
4/28 Form 8-K ELI LILLY & Co For: Apr 24 -3.5%
2/27 Local Organization NOVA ScriptsCentral Benefits BIG with Eli Lilly release of Bulk Donation Insulin Pens -3.4%
2/21 Trulicity® (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce cardiovascular events in adults with and without established cardiovascular disease -3.4%
8/5 Lilly Announces Positive Results for Emgality® (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments -3.4%
3/18 Hap Sneddon's Top Picks: March 18, 2020 [Business News Network (BNN) Energy & Resources (Canada)] -7.6%
3/20 Form DEFA14A ELI LILLY & Co -5.8%
7/11 New England Journal of Medicine Publishes Positive Phase 3 Data for Emgality® (galcanezumab-gnlm) in Episodic Cluster Headache -5.3%
6/9 Lilly's ultra rapid lispro provided similar A1C reductions compared to Humalog® (insulin lispro), with superior post-meal blood glucose reductions -4.0%
8/14 Lilly Launches Open Innovation Challenge to Help Transform Inflammatory Bowel Disease (IBD) Care through Digital Health -4.0%
4/28 Form 8-K ELI LILLY & Co For: Apr 24 -3.5%
2/27 Local Organization NOVA ScriptsCentral Benefits BIG with Eli Lilly release of Bulk Donation Insulin Pens -3.4%
2/21 Trulicity® (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce cardiovascular events in adults with and without established cardiovascular disease -3.4%
8/5 Lilly Announces Positive Results for Emgality® (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments -3.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: